Go Pro
→ Bezos… DOOMED (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-36.4%		$0.00
$0.00
▼
$0.30
$29K-9.0259,439 shs1,300 shs
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$17K-0.223,962 shs32,052 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.02
$0.01
$0.00
▼
$0.07
$79K1.414,799 shs250 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
$0.00
▼
$0.10
$14K-16.551,322 shs14 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-36.36%-12.50%-69.57%-91.36%-99.75%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-33.33%-33.33%0.00%-33.33%+33.33%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%0.00%+18.11%+18.11%-60.84%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11,000.00%+5,450.00%0.00%-55.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
-36.4%		$0.00
$0.00
▼
$0.30
$29K-9.0259,439 shs1,300 shs
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
$0.00
$0.00
$0.00
▼
$0.01
$17K-0.223,962 shs32,052 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.02
$0.01
$0.00
▼
$0.07
$79K1.414,799 shs250 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
$0.00
▼
$0.10
$14K-16.551,322 shs14 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-36.36%-12.50%-69.57%-91.36%-99.75%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-33.33%-33.33%0.00%-33.33%+33.33%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%0.00%+18.11%+18.11%-60.84%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11,000.00%+5,450.00%0.00%-55.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
0.00
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$1.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
-$11.61MN/AN/AN/AN/AN/AN/AN/A12/2/2026 (Estimated)
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$5.31N/AN/AN/AN/A-248.33%-132.73%11/10/2026 (Estimated)
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
-$15.19M-$123.25N/AN/AN/AN/A-1,554.34%-338.29%11/19/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
32.23%

Insider Ownership

CompanyInsider Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
5.10%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Scopus BioPharma Inc. stock logo
SCPS
Scopus BioPharma
1342.08 million39.94 millionNot Optionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
21.24 million4.71 millionNot Optionable

Recent News About These Companies

Virpax Pharmaceuticals stock plummets on Nasdaq delisting news
April 3, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/virpax-pharmaceuticals-stock-plummets-on-nasdaq-delisting-news-93CH-3966072
Virpax Pharmaceuticals Inc trading halted, news pending
March 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-inc-trading-halted-news-pending-1034500708
Virpax reports positive results in Probudur dog study
March 20, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-reports-positive-results-in-probudur-dog-study-93CH-3935131
Virpax receives positive Probudur results for dose range study
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-receives-positive-probudur-results-for-dose-range-study-1034490634
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-announces-1-for-25-reverse-stock-split-1034494202
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
March 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-receives-positive-probudur-results-200100643.html
Virpax Pharmaceuticals files to sell common stock and warrants, no amount given
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-files-to-sell-common-stock-and-warrants-no-amount-given-1034485903
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-explores-intranasal-mrna-vaccine-delivery-using-met/ar-AA1AGDwC
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-to-present-nes100-toxicity-study-at-major-toxicology-conference/ar-AA1AF8g0
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
March 7, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250307334228/en/virpax-looking-to-use-met-to-develop-intranasal-covid-vaccine/
Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)
March 6, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/analysts-conflicted-on-these-healthcare-names-clearside-biomedical-clsd-and-virpax-pharmaceuticals-vrpx-1034450215
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
March 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-nes100-presented-society-toxicology-210100662.html
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology
March 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/virpax-pharmaceuticals-applauds-successful-trial-of-molecular-envelope-technology/ar-AA1A7VRw
Virpax lauds Nanomerics’ MET study with no severe side effects
March 1, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-lauds-nanomerics-met-study-with-no-severe-side-effects-93CH-3897728
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-reports-positive-results-human-210100424.html
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250227128970/en/virpax-reports-positive-results-in-human-study-for-its-molecular-envelope-technology/
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
February 13, 2025  |  joplinglobe.comJ
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur
February 13, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-confirms-results-with-u-s-army-with-probudur-1034358717
Virpax reports positive study results for pain management drug
February 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-reports-positive-study-results-for-pain-management-drug/ar-AA1z0EUb
Virpax Pharmaceuticals appoints new independent director
February 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-pharmaceuticals-appoints-new-independent-director/ar-AA1yywrg

New MarketBeat Followers Over Time

Media Sentiment Over Time

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0007 0.00 (-36.36%)
As of 12:31 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Scopus BioPharma stock logo

Scopus BioPharma NASDAQ:SCPS

$0.0004 0.00 (0.00%)
As of 09/23/2026 10:24 AM Eastern

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.02 0.00 (0.00%)
As of 09/23/2026 09:30 AM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Virpax Pharmaceuticals stock logo

Virpax Pharmaceuticals NASDAQ:VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas